Biotech Stocks: Opportunities abound for Osiris Therapeutics (OSIR:NASDAQ)
May 27, 2008 at 12:30 PM EDT
‘This Maryland-based biotechnology firm develops treatments for conditions as varied as Crohn’s disease, knee arthritis, tissue damage, life-threatening Graft-versus-host disease and acute radiation syndrome.’ – Laura Cadden Osiris Therapeutics, Inc. creates therapeutic drugs from human mesenchymal stem cells (MSCs) retrieved from bone marrow donated by healthy adult volunteers. Bone regeneration = big bucks Earlier this month, Osiris announced the sale of its Osteocel unit to NuVasive for $85 million. Osteocel promotes bone regeneration and is used in spinal fusion and other orthopedic procedures. This deal provides Osiris with the money and ability to focus on the next generation of revolutionary products… products like Chondrogen, which works… SHARETHIS.addEntry({ title: "Biotech Stocks: Opportunities abound for Osiris Therapeutics (OSIR:NASDAQ)", url: "http://jutiagroup.com/2008/05/27/biotech-stocks-opportunities-abound-for-osiris-therapeutics-osirnasdaq/" });